Rhumbline Advisers acquired a new position in Audentes Therapeutics, Inc. (NASDAQ:BOLD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,181 shares of the biotechnology company’s stock, valued at approximately $252,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. TD Asset Management Inc. raised its holdings in Audentes Therapeutics by 2.4% in the 2nd quarter. TD Asset Management Inc. now owns 25,280 shares of the biotechnology company’s stock worth $484,000 after purchasing an additional 598 shares in the last quarter. Bank of America Corp DE raised its holdings in Audentes Therapeutics by 22.6% in the 1st quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 4,310 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Audentes Therapeutics by 36.2% in the 1st quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 5,009 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,700 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Audentes Therapeutics in the 1st quarter worth $184,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
In related news, SVP David Nagler sold 3,750 shares of Audentes Therapeutics stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $25.00, for a total value of $93,750.00. Following the completion of the sale, the senior vice president now directly owns 3,750 shares in the company, valued at $93,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 672,000 shares of Audentes Therapeutics stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $28.25, for a total value of $18,984,000.00. The disclosure for this sale can be found here. Insiders sold 766,500 shares of company stock valued at $21,443,730 over the last 90 days. 47.30% of the stock is currently owned by corporate insiders.
Shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) opened at 28.03 on Friday. The stock’s market capitalization is $613.55 million. The stock has a 50 day moving average of $26.82 and a 200-day moving average of $26.82. Audentes Therapeutics, Inc. has a 52-week low of $13.13 and a 52-week high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.10). Analysts predict that Audentes Therapeutics, Inc. will post ($3.50) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Invests $252,000 in Audentes Therapeutics, Inc. (BOLD) Stock” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/10/13/rhumbline-advisers-invests-252000-in-audentes-therapeutics-inc-bold-stock.html.
BOLD has been the subject of several research reports. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Monday, July 17th. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Bank of America Corporation reaffirmed a “buy” rating and issued a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Raymond James Financial, Inc. began coverage on shares of Audentes Therapeutics in a research report on Thursday. They issued a “market perform” rating on the stock. Finally, Evercore ISI began coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $24.17.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics, Inc. (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.